Therefore, we analysed ELOVL1 expression in the same scRNA-seq dataset from patients with melanoma treated with anti-PD-1 (ref. 35) and in a bulk-RNA sequencing dataset of patients with PDAC treated with anti-PD-1 and anti-CTLA-4 in combination with radiation36 (given the absence of scRNA sequencing PDAC datasets similar to those found in patients with melanoma where ICB-based therapy is the first-line treatment option). The gene discussed is CTLA4; the disease is melanoma.